AbbVie and MedinCell have made significant progress in their partnership, unveiling a new R&D pipeline that's got everyone talking. The partnership aims to develop a new class of sustained release peptide-based products.
One of the key areas of focus is the development of a sustained release formulation for a certain peptide, which has shown promising results in preclinical studies. This technology has the potential to improve the treatment of various diseases.
The partnership has also made significant strides in the development of a new peptide-based product for the treatment of a specific disease. This product is currently in the preclinical stage and has shown promising efficacy and safety profiles.
MedinCell's proprietary technology has been instrumental in the development of these new products, allowing for the creation of sustained release formulations that can improve treatment outcomes.
AbbVie and MedinCell Partnership
AbbVie and MedinCell have partnered to develop and commercialize up to six innovative therapies using MedinCell's long-acting injectable platform.
MedinCell will receive an upfront payment of $35 million and is eligible for development and commercial milestones up to $1.9 billion and royalties on net sales.
MedinCell's BEPO technology precisely controls the delivery of drugs over extended periods from a small subcutaneous injection.
The partnership will see AbbVie finance and lead clinical trials, regulatory approvals, manufacturing, and commercialization, while MedinCell will conduct formulation and preclinical studies.
MedinCell has a commercial product, UZEDY, based on its BEPO technology, which is marketed by Teva for the treatment of schizophrenia.
MedinCell is eligible to receive up to $222 million in milestones and royalties on sales of UZEDY and another long-acting olanzapine injection, mdc-TJK, developed and commercialized by Teva.
This partnership capitalizes on MedinCell's expertise in developing commercial-stage long-acting injectable therapies and AbbVie's comprehensive experience in clinical development and commercialization.
MedinCell Unveils Progress in Product and R&D Pipeline
MedinCell has made remarkable progress in its product and R&D pipeline, thanks to a partnership with AbbVie. MedinCell will receive an upfront payment of $35 million and is eligible for development and commercial milestones up to $1.9 billion and royalties on net sales.
MedinCell is working with AbbVie to develop and commercialize up to six innovative therapies using MedinCell's long-acting injectable platform.
MedinCell's BEPO technology precisely controls the delivery of drugs over extended periods from a small subcutaneous injection. It combines active ingredients with a bioresorbable deposit that releases the drug at a consistent therapeutic level, improving compliance, effectiveness, and accessibility.
MedinCell's UZEDY is the first commercial product based on its BEPO technology, and it's marketed by Teva for the treatment of schizophrenia.
MedinCell has partnered with Teva to develop and commercialize UZEDY and another long-acting olanzapine injection, mdc-TJK. MedinCell may receive up to $222 million in milestones and royalties on sales of both products.
Featured Images: pexels.com
